Showing results (21-30 of 34) with videos related to
Sort By:
Pageof 4
Transplantation and Cellular Therapy|October 9, 2021
Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of LifeNisha S Joseph, Vikas A Gupta, Sarah Wyman, et al.JCO Oncology Practice|July 7, 2023
Impact of Black Race on Peripheral Neuropathy in Patients With Newly Diagnosed Multiple Myeloma Receiving Bortezomib InductionLaura F Sun, Kathryn T Maples, Kevin H Hall, et al.Haematologica|May 30, 2015
Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)Rashid Khan, Madhav Dhodapkar, Adam Rosenthal, et al.British Journal of Haematology|January 10, 2006
Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myelomaHani Hassoun, Lilian Reich, Virginia M Klimek, et al.The Lancet. Haematology|December 28, 2020
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trialSaad Z Usmani, Antje Hoering, Sikander Ailawadhi, et al.Journal for Immunotherapy of Cancer|July 15, 2020
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myelomaNina Shah, Jack Aiello, David E Avigan, et al.British Journal of Haematology|August 31, 2006
Long-term outcome results of the first tandem autotransplant trial for multiple myelomaBart Barlogie, Guido J Tricot, Frits van Rhee, et al.Cancer Research|April 5, 2017
Precancer Atlas to Drive Precision Prevention TrialsAvrum Spira, Matthew B Yurgelun, Ludmil Alexandrov, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib StudyAlexander M Lesokhin, Stephen M Ansell, Philippe Armand, et al.Journal for Immunotherapy of Cancer|September 29, 2022
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC)Michael B Atkins, Hamzah Abu-Sbeih, Paolo A Ascierto, et al.Pageof 4